



## DSECT and CAN-AIM DSEN Joint Seminar

Presented as part of the DSECT/DSEN Monthly Seminar Series

### “Using population-based data linkages and pan-Canadian networks to investigate multiple sclerosis (MS) drug safety and effectiveness”

Presented by

**Prof. Helen Tremlett, PhD**

*Professor, Medicine (Neurology); Canada Research Chair in Multiple Sclerosis and Neuroepidemiology, University of British Columbia, Vancouver*

and

**Dr. Kaarina Kowalec, PhD**

*Postdoctoral Researcher, Medicine (Neurology),  
University of British Columbia, Vancouver*

**Thursday, January 26, 2017 at 3:00-4:00pm EST**

**Online webinar (GoToWebinar)**

**RSVP: <https://attendee.gotowebinar.com/register/553163580539082241>**

This presentation will discuss the use and linkage of population-based data to multiple sclerosis (MS) specialty clinic databases to answer questions regarding MS drug safety and effectiveness. We will also present methods on how to harness pan-Canadian and worldwide networks to identify pharmacogenomic biomarkers of serious adverse drug reactions to MS drugs, including a recent study on interferon-beta associated liver injury in MS.

**Resources:**

- Website for the Canadian Network for Advanced Interdisciplinary Methods (CAN-AIM) for comparative effectiveness research: [canaim.ca](http://canaim.ca)
- Journal articles that may be discussed during the presentation are available on the CIHR Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program website: [www.safeandeffectiverx.com](http://www.safeandeffectiverx.com)

*For more information on this webinar, please visit [www.safeandeffectiverx.com](http://www.safeandeffectiverx.com) or contact Melissa Pirrie ([pirrie@mcmaster.ca](mailto:pirrie@mcmaster.ca)).*